ID   MCF2_HUMAN              Reviewed;         925 AA.
AC   P10911; B7Z3Y5; B7Z869; B7ZAV1; E9PH77; F5H091; P14919; Q5JYJ2; Q5JYJ3;
AC   Q5JYJ4; Q8IUF3; Q8IUF4; Q9UJB3;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 3.
DT   28-JUN-2023, entry version 222.
DE   RecName: Full=Proto-oncogene DBL;
DE   AltName: Full=Proto-oncogene MCF-2;
DE   Contains:
DE     RecName: Full=MCF2-transforming protein;
DE   Contains:
DE     RecName: Full=DBL-transforming protein;
GN   Name=MCF2; Synonyms=DBL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=3056717; DOI=10.1002/j.1460-2075.1988.tb03093.x;
RA   Ron D., Tronick S.R., Aaronson S.A., Eva A.;
RT   "Molecular cloning and characterization of the human dbl proto-oncogene:
RT   evidence that its overexpression is sufficient to transform NIH/3T3
RT   cells.";
RL   EMBO J. 7:2465-2473(1988).
RN   [2]
RP   SEQUENCE REVISION.
RA   Ron D.;
RL   Submitted (JUN-1989) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), TISSUE SPECIFICITY, AND
RP   CHARACTERIZATION.
RX   PubMed=12445822; DOI=10.1016/s0006-291x(02)02645-1;
RA   Komai K., Okayama R., Kitagawa M., Yagi H., Chihara K., Shiozawa S.;
RT   "Alternative splicing variants of the human DBL (MCF-2) proto-oncogene.";
RL   Biochem. Biophys. Res. Commun. 299:455-458(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Rhodes S., Huckle E.;
RL   Submitted (SEP-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 5 AND 6).
RC   TISSUE=Testis, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 498-925 (ISOFORM 1).
RX   PubMed=3281159; DOI=10.1073/pnas.85.7.2061;
RA   Eva A., Vecchio G., Rao C.D., Tronick S.R., Aaronson S.A.;
RT   "The predicted DBL oncogene product defines a distinct class of
RT   transforming proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:2061-2065(1988).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 398-925 (ISOFORM 1).
RX   PubMed=2577874;
RA   Noguchi T., Galland F., Batoz M., Mattei M.-G., Birnbaum D.;
RT   "Activation of a mcf.2 oncogene by deletion of amino-terminal coding
RT   sequences.";
RL   Oncogene 3:709-715(1988).
RN   [10]
RP   DOMAIN DBL-HOMOLOGY, AND MUTAGENESIS.
RX   PubMed=2065022;
RA   Ron D., Zannini M., Lewis M., Wickner R.B., Hunt L.T., Graziani G.,
RA   Tronick S.R., Aaronson S.A., Eva A.;
RT   "A region of proto-dbl essential for its transforming activity shows
RT   sequence similarity to a yeast cell cycle gene, CDC24, and the human
RT   breakpoint cluster gene, bcr.";
RL   New Biol. 3:372-379(1991).
RN   [11]
RP   CHARACTERIZATION OF DBL DOMAIN.
RX   PubMed=8276860; DOI=10.1016/s0021-9258(17)42313-1;
RA   Hart M.J., Eva A., Zangrilli D., Aaronson S.A., Evans T., Cerione R.A.,
RA   Zheng Y.;
RT   "Cellular transformation and guanine nucleotide exchange activity are
RT   catalyzed by a common domain on the dbl oncogene product.";
RL   J. Biol. Chem. 269:62-65(1994).
RN   [12]
RP   PHOSPHORYLATION BY TNK2.
RX   PubMed=10652228; DOI=10.1006/bbrc.2000.2106;
RA   Kato J., Kaziro Y., Satoh T.;
RT   "Activation of the guanine nucleotide exchange factor Dbl following ACK1-
RT   dependent tyrosine phosphorylation.";
RL   Biochem. Biophys. Res. Commun. 268:141-147(2000).
RN   [13]
RP   SUBCELLULAR LOCATION, DOMAIN CRAL-TRIO, AND INTERACTION WITH INOSITOL
RP   PHOSPHOLIPIDS.
RX   PubMed=15157669; DOI=10.1016/j.cellsig.2004.01.007;
RA   Ueda S., Kataoka T., Satoh T.;
RT   "Role of the Sec14-like domain of Dbl family exchange factors in the
RT   regulation of Rho family GTPases in different subcellular sites.";
RL   Cell. Signal. 16:899-906(2004).
RN   [14]
RP   POSSIBLE INTERACTION WITH CCPG1.
RX   PubMed=17000758; DOI=10.1128/mcb.00670-06;
RA   Kostenko E.V., Olabisi O.O., Sahay S., Rodriguez P.L., Whitehead I.P.;
RT   "Ccpg1, a novel scaffold protein that regulates the activity of the Rho
RT   guanine nucleotide exchange factor Dbs.";
RL   Mol. Cell. Biol. 26:8964-8975(2006).
CC   -!- FUNCTION: Guanine nucleotide exchange factor (GEF) that modulates the
CC       Rho family of GTPases. Promotes the conversion of some member of the
CC       Rho family GTPase from the GDP-bound to the GTP-bound form. Isoform 1
CC       exhibits no activity toward RHOA, RAC1 or CDC42. Isoform 2 exhibits
CC       decreased GEF activity toward CDC42. Isoform 3 exhibits a weak but
CC       significant activity toward RAC1 and CDC42. Isoform 4 exhibits
CC       significant activity toward RHOA and CDC42. The truncated DBL oncogene
CC       is active toward RHOA, RAC1 and CDC42.
CC   -!- SUBUNIT: Interacts with an array of inositol phospholipids such as
CC       phosphatidylinositol 3-phosphate (PI3P), phosphatidylinositol 4-
CC       phosphate (PI4P) and phosphatidylinositol 5-phosphate (PI5P). May
CC       interact with CCPG1. {ECO:0000269|PubMed:15157669}.
CC   -!- INTERACTION:
CC       P10911; P15531: NME1; NbExp=4; IntAct=EBI-1914514, EBI-741141;
CC       PRO_0000030434; P15531: NME1; NbExp=9; IntAct=EBI-1915491, EBI-741141;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15157669}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Membrane.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Membrane. Note=Colocalizes with
CC       CDC42 to plasma membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=Var.1;
CC         IsoId=P10911-1; Sequence=Displayed;
CC       Name=2; Synonyms=Var.2;
CC         IsoId=P10911-2; Sequence=VSP_008151, VSP_008152;
CC       Name=3; Synonyms=Var.3;
CC         IsoId=P10911-3; Sequence=VSP_008150;
CC       Name=4; Synonyms=Var.4;
CC         IsoId=P10911-4; Sequence=VSP_008153;
CC       Name=5;
CC         IsoId=P10911-5; Sequence=VSP_008150, VSP_008153;
CC       Name=6;
CC         IsoId=P10911-6; Sequence=VSP_046118, VSP_008151, VSP_008152;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed only in brain. Isoform 3 is
CC       expressed in heart, kidney, spleen, liver and testis. Isoform 4 is
CC       expressed in brain, heart, kidney, testis, placenta, stomach and
CC       peripheral blood. The protein is detectable in brain, heart, kidney,
CC       intestine, muscle, lung and testis. {ECO:0000269|PubMed:12445822}.
CC   -!- DOMAIN: The CRAL-TRIO domain is involved in interaction with inositol
CC       phospholipids.
CC   -!- DOMAIN: The DH domain is essential for transforming activity and
CC       directly catalyzes GDP-GTP exchange activity. It may interact with
CC       CCPG1.
CC   -!- PTM: Phosphorylation by TNK2 enhances guanine nucleotide exchange
CC       factor (GEF) activity toward Rho family proteins.
CC       {ECO:0000269|PubMed:10652228}.
CC   -!- DISEASE: Note=MCF2 and DBL represent two activated versions of the same
CC       proto-oncogene. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the MCF2 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA52172.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X12556; CAA31069.1; -; mRNA.
DR   EMBL; AB085901; BAC41200.1; -; mRNA.
DR   EMBL; AB085902; BAC41201.1; -; mRNA.
DR   EMBL; AL117234; CAB55301.1; -; mRNA.
DR   EMBL; AK296488; BAH12371.1; -; mRNA.
DR   EMBL; AK302957; BAH13855.1; -; mRNA.
DR   EMBL; AK316416; BAH14787.1; -; mRNA.
DR   EMBL; AL033403; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL161777; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471150; EAW88427.1; -; Genomic_DNA.
DR   EMBL; CH471150; EAW88430.1; -; Genomic_DNA.
DR   EMBL; J03639; AAA52172.1; ALT_INIT; mRNA.
DR   EMBL; X13230; CAA31617.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS14667.1; -. [P10911-1]
DR   CCDS; CCDS48175.1; -. [P10911-3]
DR   CCDS; CCDS55514.1; -. [P10911-6]
DR   CCDS; CCDS55515.1; -. [P10911-2]
DR   CCDS; CCDS55516.1; -. [P10911-4]
DR   CCDS; CCDS55517.1; -. [P10911-5]
DR   PIR; A28051; TVHUBD.
DR   PIR; A30040; TVHUDB.
DR   PIR; S10138; S10138.
DR   RefSeq; NP_001093325.1; NM_001099855.1. [P10911-3]
DR   RefSeq; NP_001165347.1; NM_001171876.1. [P10911-5]
DR   RefSeq; NP_001165348.1; NM_001171877.1. [P10911-6]
DR   RefSeq; NP_001165349.1; NM_001171878.1. [P10911-2]
DR   RefSeq; NP_001165350.1; NM_001171879.1. [P10911-4]
DR   RefSeq; NP_005360.3; NM_005369.4. [P10911-1]
DR   RefSeq; XP_011529641.1; XM_011531339.2. [P10911-5]
DR   RefSeq; XP_016885020.1; XM_017029531.1. [P10911-5]
DR   AlphaFoldDB; P10911; -.
DR   SMR; P10911; -.
DR   BioGRID; 110336; 16.
DR   CORUM; P10911; -.
DR   IntAct; P10911; 5.
DR   MINT; P10911; -.
DR   STRING; 9606.ENSP00000430276; -.
DR   ChEMBL; CHEMBL4523650; -.
DR   SwissLipids; SLP:000001545; -.
DR   iPTMnet; P10911; -.
DR   PhosphoSitePlus; P10911; -.
DR   BioMuta; MCF2; -.
DR   DMDM; 92087039; -.
DR   MassIVE; P10911; -.
DR   PaxDb; P10911; -.
DR   PeptideAtlas; P10911; -.
DR   ProteomicsDB; 20475; -.
DR   ProteomicsDB; 25269; -.
DR   ProteomicsDB; 52668; -. [P10911-1]
DR   ProteomicsDB; 52669; -. [P10911-2]
DR   ProteomicsDB; 52670; -. [P10911-3]
DR   ProteomicsDB; 52671; -. [P10911-4]
DR   Antibodypedia; 4174; 140 antibodies from 23 providers.
DR   DNASU; 4168; -.
DR   Ensembl; ENST00000338585.6; ENSP00000342204.6; ENSG00000101977.22. [P10911-4]
DR   Ensembl; ENST00000370573.8; ENSP00000359605.4; ENSG00000101977.22. [P10911-2]
DR   Ensembl; ENST00000370576.9; ENSP00000359608.4; ENSG00000101977.22. [P10911-1]
DR   Ensembl; ENST00000414978.5; ENSP00000397055.1; ENSG00000101977.22. [P10911-3]
DR   Ensembl; ENST00000519895.6; ENSP00000430276.1; ENSG00000101977.22. [P10911-5]
DR   Ensembl; ENST00000536274.5; ENSP00000438155.1; ENSG00000101977.22. [P10911-6]
DR   GeneID; 4168; -.
DR   KEGG; hsa:4168; -.
DR   MANE-Select; ENST00000519895.6; ENSP00000430276.1; NM_001171876.2; NP_001165347.1. [P10911-5]
DR   UCSC; uc004fau.4; human. [P10911-1]
DR   AGR; HGNC:6940; -.
DR   CTD; 4168; -.
DR   DisGeNET; 4168; -.
DR   GeneCards; MCF2; -.
DR   HGNC; HGNC:6940; MCF2.
DR   HPA; ENSG00000101977; Tissue enhanced (adrenal gland, seminal vesicle, testis).
DR   MIM; 311030; gene.
DR   neXtProt; NX_P10911; -.
DR   OpenTargets; ENSG00000101977; -.
DR   PharmGKB; PA30684; -.
DR   VEuPathDB; HostDB:ENSG00000101977; -.
DR   eggNOG; KOG4240; Eukaryota.
DR   GeneTree; ENSGT00940000156974; -.
DR   HOGENOM; CLU_007130_1_0_1; -.
DR   InParanoid; P10911; -.
DR   OrthoDB; 4244290at2759; -.
DR   PhylomeDB; P10911; -.
DR   TreeFam; TF318080; -.
DR   PathwayCommons; P10911; -.
DR   Reactome; R-HSA-193634; Axonal growth inhibition (RHOA activation).
DR   Reactome; R-HSA-193648; NRAGE signals death through JNK.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-8980692; RHOA GTPase cycle.
DR   Reactome; R-HSA-9013026; RHOB GTPase cycle.
DR   Reactome; R-HSA-9013106; RHOC GTPase cycle.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013408; RHOG GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   SignaLink; P10911; -.
DR   SIGNOR; P10911; -.
DR   BioGRID-ORCS; 4168; 9 hits in 773 CRISPR screens.
DR   ChiTaRS; MCF2; human.
DR   GeneWiki; MCF2; -.
DR   GenomeRNAi; 4168; -.
DR   Pharos; P10911; Tbio.
DR   PRO; PR:P10911; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P10911; protein.
DR   Bgee; ENSG00000101977; Expressed in adrenal tissue and 140 other tissues.
DR   ExpressionAtlas; P10911; baseline and differential.
DR   Genevisible; P10911; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005856; C:cytoskeleton; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0019898; C:extrinsic component of membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IBA:GO_Central.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:0016358; P:dendrite development; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0050771; P:negative regulation of axonogenesis; TAS:Reactome.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   CDD; cd00160; RhoGEF; 1.
DR   CDD; cd00176; SPEC; 1.
DR   Gene3D; 1.20.58.60; -; 1.
DR   Gene3D; 1.20.900.10; Dbl homology (DH) domain; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   InterPro; IPR001251; CRAL-TRIO_dom.
DR   InterPro; IPR035899; DBL_dom_sf.
DR   InterPro; IPR000219; DH-domain.
DR   InterPro; IPR001331; GDS_CDC24_CS.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR018159; Spectrin/alpha-actinin.
DR   PANTHER; PTHR22826:SF146; PROTO-ONCOGENE DBL; 1.
DR   PANTHER; PTHR22826; RHO GUANINE EXCHANGE FACTOR-RELATED; 1.
DR   Pfam; PF13716; CRAL_TRIO_2; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00621; RhoGEF; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00325; RhoGEF; 1.
DR   SMART; SM00150; SPEC; 1.
DR   SUPFAM; SSF48065; DBL homology domain (DH-domain); 1.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   SUPFAM; SSF46966; Spectrin repeat; 1.
DR   PROSITE; PS50191; CRAL_TRIO; 1.
DR   PROSITE; PS00741; DH_1; 1.
DR   PROSITE; PS50010; DH_2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cytoplasm; Guanine-nucleotide releasing factor;
KW   Membrane; Phosphoprotein; Proto-oncogene; Reference proteome.
FT   CHAIN           1..925
FT                   /note="Proto-oncogene DBL"
FT                   /id="PRO_0000030432"
FT   CHAIN           398..925
FT                   /note="MCF2-transforming protein"
FT                   /id="PRO_0000030433"
FT   CHAIN           498..925
FT                   /note="DBL-transforming protein"
FT                   /id="PRO_0000030434"
FT   DOMAIN          1..88
FT                   /note="CRAL-TRIO"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00056"
FT   REPEAT          221..322
FT                   /note="Spectrin"
FT   DOMAIN          495..675
FT                   /note="DH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00062"
FT   DOMAIN          687..809
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   VAR_SEQ         1..17
FT                   /note="MAEANPRRGKMRFRRNA -> MQDIAFLSGGRGKDNAWIITFPENCNFRCIP
FT                   EEVIAKVLTYLTSIARQNGSDSRFTIILDRRLDTWSSLKISLQKIS (in isoform
FT                   3 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:12445822,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|Ref.4"
FT                   /id="VSP_008150"
FT   VAR_SEQ         58..96
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046118"
FT   VAR_SEQ         454
FT                   /note="Q -> QVGVGYSFFQACKLFSK (in isoform 4 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:12445822,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_008153"
FT   VAR_SEQ         842..860
FT                   /note="KQQGAFISTEETELEHTST -> DLCRRWLSYIDEATMSNGK (in
FT                   isoform 2 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:12445822,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_008151"
FT   VAR_SEQ         861..925
FT                   /note="Missing (in isoform 2 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:12445822,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_008152"
FT   MUTAGEN         640..646
FT                   /note="LLLKELL->IIIRDII: Transformation capability reduced;
FT                   no stimulation of GDP dissociation."
FT                   /evidence="ECO:0000269|PubMed:2065022"
FT   CONFLICT        54
FT                   /note="L -> P (in Ref. 1 and 3)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        178
FT                   /note="C -> S (in Ref. 5; BAH12371)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        330
FT                   /note="L -> F (in Ref. 5; BAH14787)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        358
FT                   /note="D -> Y (in Ref. 5; BAH12371)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        634
FT                   /note="R -> Q (in Ref. 8)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        687
FT                   /note="N -> I (in Ref. 5; BAH14787)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        886
FT                   /note="A -> V (in Ref. 9)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        900
FT                   /note="F -> S (in Ref. 5; BAH13855)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   925 AA;  107673 MW;  96233C7AFC85D637 CRC64;
     MAEANPRRGK MRFRRNAASF PGNLHLVLVL RPTSFLQRTF TDIGFWFSQE DFMLKLPVVM
     LSSVSDLLTY IDDKQLTPEL GGTLQYCHSE WIIFRNAIEN FALTVKEMAQ MLQSFGTELA
     ETELPDDIPS IEEILAIRAE RYHLLKNDIT AVTKEGKILL TNLEVPDTEG AVSSRLECHR
     QISGDWQTIN KLLTQVHDME TAFDGFWEKH QLKMEQYLQL WKFEQDFQQL VTEVEFLLNQ
     QAELADVTGT IAQVKQKIKK LENLDENSQE LLSKAQFVIL HGHKLAANHH YALDLICQRC
     NELRYLSDIL VNEIKAKRIQ LSRTFKMHKL LQQARQCCDE GECLLANQEI DKFQSKEDAQ
     KALQDIENFL EMALPFINYE PETLQYEFDV ILSPELKVQM KTIQLKLENI RSIFENQQAG
     FRNLADKHVR PIQFVVPTPE NLVTSGTPFF SSKQGKKTWR QNQSNLKIEV VPDCQEKRSS
     GPSSSLDNGN SLDVLKNHVL NELIQTERVY VRELYTVLLG YRAEMDNPEM FDLMPPLLRN
     KKDILFGNMA EIYEFHNDIF LSSLENCAHA PERVGPCFLE RKDDFQMYAK YCQNKPRSET
     IWRKYSECAF FQECQRKLKH RLRLDSYLLK PVQRITKYQL LLKELLKYSK DCEGSALLKK
     ALDAMLDLLK SVNDSMHQIA INGYIGNLNE LGKMIMQGGF SVWIGHKKGA TKMKDLARFK
     PMQRHLFLYE KAIVFCKRRV ESGEGSDRYP SYSFKHCWKM DEVGITEYVK GDNRKFEIWY
     GEKEEVYIVQ ASNVDVKMTW LKEIRNILLK QQELLTVKKR KQQDQLTERD KFQISLQQND
     EKQQGAFIST EETELEHTST VVEVCEAIAS VQAEANTVWT EASQSAEISE EPAEWSSNYF
     YPTYDENEEE NRPLMRPVSE MALLY
//
